New Frontiers in Gene-Modified T Cell Technology PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download New Frontiers in Gene-Modified T Cell Technology PDF full book. Access full book title New Frontiers in Gene-Modified T Cell Technology by Ignazio Caruana. Download full books in PDF and EPUB format.
Author: Ignazio Caruana Publisher: Frontiers Media SA ISBN: 283255041X Category : Medical Languages : en Pages : 222
Book Description
The development, clinical translation and recent efficacy of novel gene therapies targeting refractory malignancies has led to research that extends this technology to a variety of infectious and rheumatological diseases. Unlike conventional drugs or antibodies, T cells have the potential to target and exert effector function in response to disease in a dynamic manner, acting as a “living drug”. The most efficacious form of gene-modified T cells to date is the chimeric antigen receptor (CAR)-modified T cell, which redirects the specificity of T cells to an antigen expressed by tumor cells. Clinical experience with autologous CAR-T cells, primarily in hematologic malignancies, has underscored the feasibility and safety of the approach, while also demonstrating dramatic and sustained antitumor effects through mechanisms orthogonal to those of traditional anticancer therapies. However, several challenging obstacles must be surmounted in order to improve the broader efficacy of this approach.
Author: Ignazio Caruana Publisher: Frontiers Media SA ISBN: 283255041X Category : Medical Languages : en Pages : 222
Book Description
The development, clinical translation and recent efficacy of novel gene therapies targeting refractory malignancies has led to research that extends this technology to a variety of infectious and rheumatological diseases. Unlike conventional drugs or antibodies, T cells have the potential to target and exert effector function in response to disease in a dynamic manner, acting as a “living drug”. The most efficacious form of gene-modified T cells to date is the chimeric antigen receptor (CAR)-modified T cell, which redirects the specificity of T cells to an antigen expressed by tumor cells. Clinical experience with autologous CAR-T cells, primarily in hematologic malignancies, has underscored the feasibility and safety of the approach, while also demonstrating dramatic and sustained antitumor effects through mechanisms orthogonal to those of traditional anticancer therapies. However, several challenging obstacles must be surmounted in order to improve the broader efficacy of this approach.
Author: Magdalena Klink Publisher: Springer Nature ISBN: 3030913112 Category : Medical Languages : en Pages : 358
Book Description
Now, it its second edition, this book summarizes the role of immune cells in tumor suppression and progression. It describes in detail why tumor cells can survive and spread in spite of the antitumor response of immune cells. Since immunotherapy is an attractive approach to cancer therapy, this book also provides information on the two main strategies: monoclonal antibodies and adaptive T cell immunotherapy, with a focus on recent human clinical trials. A newly added chapter also focuses on the role of Natural Killer cells in tumor progression. The book provides a state-of-the-art, comprehensive overview of immune cells in cancer and is an indispensable resource for researchers and practitioners working or lecturing in the field of cancer research and immunology.
Author: Shivaani Kummar Publisher: Academic Press ISBN: 0128125705 Category : Medical Languages : en Pages : 235
Book Description
Novel Designs of Early Phase Trials for Cancer Therapeutics provides a comprehensive review by leaders in the field of the process of drug development, the integration of molecular profiling, the changes in early phase trial designs, and endpoints to optimally develop a new generation of cancer therapeutics. The book discusses topics such as statistical perspectives on cohort expansions, the role and application of molecular profiling and how to integrate biomarkers in early phase trials. Additionally, it discusses how to incorporate patient reported outcomes in phase one trials. This book is a valuable resource for medical oncologists, basic and translational biomedical scientists, and trainees in oncology and pharmacology who are interested in learning how to improve their research by using early phase trials. Brings a comprehensive review and recommendations for new clinical trial designs for modern cancer therapeutics Provides the reader with a better understanding on how to design and implement early phase oncology trials Presents a better and updated understanding of the process of developing new treatments for cancer, the exciting scientific advances and how they are informing drug development
Author: Maria Cristina Galli Publisher: Springer ISBN: 3319186183 Category : Medical Languages : en Pages : 235
Book Description
This book discusses the different regulatory pathways for gene therapy (GT) and cell therapy (CT) medicinal products implemented by national and international bodies throughout the world (e.g. North and South America, Europe, and Asia). Each chapter, authored by experts from various regulatory bodies throughout the international community, walks the reader through the applications of nonclinical research to translational clinical research to licensure for these innovative products. More specifically, each chapter offers insights into fundamental considerations that are essential for developers of CT and GT products, in the areas of product manufacturing, pharmacology and toxicology, and clinical trial design, as well as pertinent "must-know" guidelines and regulations. Regulatory Aspects of Gene Therapy and Cell Therapy Products: A Global Perspective is part of the American Society of Gene and Cell Therapy sub-series of the highly successful Advances in Experimental Medicine and Biology series. It is essential reading for graduate students, clinicians, and researchers interested in gene and cell therapy and the regulation of pharmaceuticals.
Author: National Academies of Sciences, Engineering, and Medicine Publisher: National Academies Press ISBN: 0309437385 Category : Science Languages : en Pages : 607
Book Description
Genetically engineered (GE) crops were first introduced commercially in the 1990s. After two decades of production, some groups and individuals remain critical of the technology based on their concerns about possible adverse effects on human health, the environment, and ethical considerations. At the same time, others are concerned that the technology is not reaching its potential to improve human health and the environment because of stringent regulations and reduced public funding to develop products offering more benefits to society. While the debate about these and other questions related to the genetic engineering techniques of the first 20 years goes on, emerging genetic-engineering technologies are adding new complexities to the conversation. Genetically Engineered Crops builds on previous related Academies reports published between 1987 and 2010 by undertaking a retrospective examination of the purported positive and adverse effects of GE crops and to anticipate what emerging genetic-engineering technologies hold for the future. This report indicates where there are uncertainties about the economic, agronomic, health, safety, or other impacts of GE crops and food, and makes recommendations to fill gaps in safety assessments, increase regulatory clarity, and improve innovations in and access to GE technology.
Author: Bourama Toni Publisher: Springer ISBN: 3319077554 Category : Mathematics Languages : en Pages : 405
Book Description
This highly multidisciplinary volume contains contributions from leading researchers in STEAM-H disciplines (Science, Technology, Engineering, Agriculture, Mathematics and Health). The volume explores new frontiers in multidisciplinary research, including: the mathematics of cardiac arrhythmia; brain research on working memory; penalized ordinal regression to classify melanoma skin samples; forecasting of time series data; dynamics of niche models; analysis of chemical moieties as anticancer agents; study of gene locus control regions; qualitative mathematical modelling; convex quadrics and group circle systems; remanufacturing planning and control; complexity reduction of functional differential equations; computation of viscous interfacial motion; and differentiation in human pluripotent stem cells. An extension of a seminar series at Virginia State University, the collection is intended to foster student interest and participation in interdisciplinary research and to stimulate new research. The content will be of interest to a broad spectrum of scientists, mathematicians and research students working in interdisciplinary fields including the biosciences, mathematics, engineering, neurosciences and behavioral sciences.
Author: Israel Vlodavsky Publisher: Springer Nature ISBN: 3030345211 Category : Medical Languages : en Pages : 871
Book Description
Written by internationally recognized leaders in Heparanase biology, the book’s eight chapters offer an opportunity for scientists, clinicians and advanced students in cell biology, tumor biology and oncology to obtain a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications. Proteases and their involvement in cancer progression have been well addressed and documented; however, the emerging premise presented within this book is that Heparanase is a master regulator of aggressive cancer phenotypes and crosstalk with the tumor microenvironment. This endoglycosidase contributes to tumor-mediated remodeling of the extracellular matrix and cell surfaces, augmenting the bioavailability of pro-tumorigenic and pro-inflammatory growth factors and cytokines that are bound to Heparan sulfate. Compelling evidence ties Heparanase with all steps of tumor progression including tumor initiation, growth, angiogenesis, metastasis, and chemoresistance, supporting the notion that Heparanase is an important contributor to the poor outcome of cancer patients and a validated target for therapy. Unlike Heparanase, heparanase-2, a close homolog of Heparanase, lacks enzymatic activity, inhibits Heparanase, and regulates selected genes that promote normal differentiation and tumor suppression. Written by internationally recognized leaders in Heparanase biology, this volume presents a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications to scientists, clinicians and advanced students in cell biology, tumor biology and oncology.
Author: Ignazio Caruana
Author: Ignazio Caruana
Author: Baptiste Durand
Author: Magdalena Klink
Author: Shivaani Kummar
Author: Maria Cristina Galli
Author: National Academies of Sciences, Engineering, and Medicine
Author: Bourama Toni
Author: L.E. Samelson
Author: Julie G. Burel
Author: Israel Vlodavsky